Annexin-Vivo 750 imaging agent for measuring cell death in vivo VisEn Medical Inc., a innovator in fluorescence in vivo imaging from analysis through medicine, announced today the industrial launch of its new Annexin-Vivo 750 imaging agent for calculating and monitoring apoptosis and cell loss of life in vivo. The new Annexin-Vivo 750 agent is based on the more developed Annexin labeling standard in in vitro study impotence click here . It is likely to significantly expand research areas and enhance medication development by enabling real-time imaging of apoptosis and cell death biomarkers associated with disease progression and therapeutic response in vivo.
This finding ought to be of immediate concern to surgeons, dentists, and any other health care professionals who anesthetize patients with Alzheimer’s or patients at an elevated risk for the disease. Related StoriesGriffith University uncovers 1st 3-D image of protein linked to cancer spreadResearchers successfully fix nerve cell harm in Alzheimer's dementiaRice researchers solve long-position mystery about hemophilia protein We hope that research will initiate a pastime in taking safety measures to limit the effect of anesthesia on the disease, said Emmanuel Planel of Columbia University Medical Center and one of the scientists involved in the work. To create this discovery, the scientists used two sets of mice that produce the abnormal tau proteins that accumulates in Alzheimer’s individuals.